All Phenotypes Tg(TcraTcrb)8Rest MGI Mouse

Phenotypes associated with this allele

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Pgd^tm1.1Pse/Pgd^tm1.1Pse Tg(Cd4-cre)1Cwi/0 Tg(TcraTcrb)8Rest/0	involves: C57BL/6 * DBA/2	MGI:6751656
cx2	Ctla4^tm1All/Ctla4^tm1All Rag1^tm1Mom/Rag1^tm1Mom Tg(TcraTcrb)8Rest/0	involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6	MGI:4940117
cx3	Ctla4^tm1All/Ctla4^tm1All Tg(TcraTcrb)8Rest/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6	MGI:4940116
tg4	Tg(TcraTcrb)8Rest/?	C57BL/6-Tg(TcraTcrb)8Rest	MGI:3789128

Allelic Composition	Pgd^tm1.1Pse/Pgd^tm1.1Pse Tg(Cd4-cre)1Cwi/0 Tg(TcraTcrb)8Rest/0
Genetic Background	involves: C57BL/6 * DBA/2

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Pgd^tm1.1Pse mutation (0 available); any Pgd mutation (21 available)
Tg(Cd4-cre)1Cwi mutation (10 available)
Tg(TcraTcrb)8Rest mutation (1 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

immune system

abnormal CD8-positive, alpha-beta T cell physiology ( J:306553 )

• CD8+ T cells co-cultured with B16-F10 melanoma cells uptake glucose more effectively than control cells

• adaptive transfer of mutant CD8+ T cells to congenic recipients bearing the B16-F10 melanoma results in smaller tumor growth than in controls

hematopoietic system

abnormal CD8-positive, alpha-beta T cell physiology ( J:306553 )

• CD8+ T cells co-cultured with B16-F10 melanoma cells uptake glucose more effectively than control cells

• adaptive transfer of mutant CD8+ T cells to congenic recipients bearing the B16-F10 melanoma results in smaller tumor growth than in controls

Allelic Composition	Ctla4^tm1All/Ctla4^tm1All Rag1^tm1Mom/Rag1^tm1Mom Tg(TcraTcrb)8Rest/0
Genetic Background	involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ctla4^tm1All mutation (2 available); any Ctla4 mutation (53 available)
Rag1^tm1Mom mutation (49 available); any Rag1 mutation (120 available)
Tg(TcraTcrb)8Rest mutation (1 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

mortality/aging ( J:140448 )

N	• mice exhibit a normal lifespan

immune system

immune system phenotype ( J:140448 )

N	• CD8+ T cells exhibit a completely naive phenotype

pigmentation

pigmentation phenotype ( J:140448 )

N	• mice do not develop autoimmune vitiligo

Allelic Composition	Ctla4^tm1All/Ctla4^tm1All Tg(TcraTcrb)8Rest/0
Genetic Background	involves: 129S1/Sv * 129X1/SvJ * C57BL/6

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ctla4^tm1All mutation (2 available); any Ctla4 mutation (53 available)
Tg(TcraTcrb)8Rest mutation (1 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

premature death ( J:140448 )

• mice die at 10 to 12 weeks

immune system

increased CD4-positive, alpha-beta T cell number ( J:140448 )

decreased CD8-positive, alpha-beta T cell number ( J:140448 )

increased interferon-gamma secretion ( J:140448 )

• hgp100(25-33)-treated splenocyte exhibit increased IFN-gamma secretion compared with splenocytes from Tg(TcraTcrb)8Rest mice

pigmentation

variable depigmentation ( J:140448 )

• at 4 to 6 weeks, 48 of 49 mice develop autoimmune vitiligo unlike Tg(TcraTcrb)8Rest mice

hematopoietic system

increased CD4-positive, alpha-beta T cell number ( J:140448 )

decreased CD8-positive, alpha-beta T cell number ( J:140448 )

integument

variable depigmentation ( J:140448 )

• at 4 to 6 weeks, 48 of 49 mice develop autoimmune vitiligo unlike Tg(TcraTcrb)8Rest mice

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

immune system

abnormal CD8-positive, alpha-beta cytotoxic T cell morphology ( J:85058 )

• over 95 % of the CD8 T cells present in circulation express the transgenic TCR that is specific for the H2-D^b restricted epitope of Silv (gp100), a protein that is highly expressed in melanoma cells

• these transgenic T cells constitute about 20% of spleen cells

• the baseline levels of activation markers for the transgenic T cells indicate that most of cells are in a nave state

abnormal cytotoxic T cell physiology ( J:85058 )

• upon in vitro stimulation with the immunogenic epitope of gp100, CD8 T cells are activated and proliferate extensively

increased interferon-gamma secretion ( J:85058 )

• CD 8 T cells produce large amounts of IFN-gamma when cultured in the presence of melanoma cells

• large number of IFN-gamma producing CD8 T cells are found in melanoma tumors that have regressed due to treatment with gp100 vaccine, IL-2, and adoptive transfer of transgenic CD8 T cells

neoplasm

abnormal tumor susceptibility ( J:85058 )

• despite the presence of large number of anti-gp100 CD8 T cells, transplanted melanoma tumors that express gp100 have the same growth kinetics as tumors transplanted into control mice

• adoptive transfer of transgenic splenocytes into normal mice bearing melanoma tumors also has no effect on tumor growth

• there is a modest delay in tumor growth when mice that are recipients of transgenic T cells are also vaccinated with peptides that mimic the gp100 epitope

• when IL-2 is administered with the vaccine, there is a large regression in tumor size in mice that are also recipients of transgenic T cells

• mice bearing melanoma tumors that receive vaccine, transgenic T cells, and IL-2 have survival times of over 1 year compared to controls that die within 2 months

hematopoietic system

abnormal CD8-positive, alpha-beta cytotoxic T cell morphology ( J:85058 )

• these transgenic T cells constitute about 20% of spleen cells

• the baseline levels of activation markers for the transgenic T cells indicate that most of cells are in a nave state

abnormal cytotoxic T cell physiology ( J:85058 )

• upon in vitro stimulation with the immunogenic epitope of gp100, CD8 T cells are activated and proliferate extensively

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 04/16/2024 MGI 6.23